NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
NervGen (NASDAQ: NGEN) said its CEO Adam Rogers, MD, and executive team will participate in two investor events in April 2026: the H.C. Wainwright “HCW@Home” fireside chat on April 15, 2026 and the Bloom Burton Healthcare Investor Conference presentation and 1x1 meetings in Toronto on April 22, 2026.
Both events will offer a live webcast and archived replay; presentation formats include a virtual fireside chat and a corporate presentation with investor meetings. According to the company, webcasts will be available on the investor section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – NGEN
In the Apr 13 session, NGEN gained 0.99%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Phase 3 alignment | Positive | -9.6% | FDA End-of-Phase 2 meeting and alignment on Phase 3 RESTORE trial. |
| Mar 31 | Earnings and update | Neutral | +1.1% | Full-year 2025 results and confirmation of Phase 3 timing and data plans. |
| Mar 12 | TSXV delisting | Positive | -7.0% | Voluntary TSXV delisting to cut costs and focus on Nasdaq listing. |
| Mar 04 | Leadership hires | Positive | +8.1% | Appointments to strengthen regulatory affairs and patient advocacy functions. |
| Feb 18 | Investor conferences | Neutral | +1.2% | Executive participation in several investor conferences and 1x1 meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw negative reactions to fundamentally positive developments (FDA alignment, TSXV delisting), while neutral or incremental items like conferences and appointments tended to produce modest gains.
Over the past two months, NervGen has advanced NVG-291 toward late-stage development, including a successful End-of-Phase 2 FDA meeting and plans for the Phase 3 RESTORE study in chronic tetraplegia. Corporate steps included voluntary TSXV delisting to focus on Nasdaq trading and cost efficiency, as well as senior hires in regulatory and patient advocacy. Prior investor conference participation on Feb 18 produced a small positive move. Today’s announcement of additional conferences continues this pattern of proactive investor engagement rather than a new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate in the H.C. Wainwright “HCW@Home” series and the 2026 Bloom Burton & Co. Healthcare Investor Conference.
H.C. Wainwright “HCW@Home” Series, April 15, 2026
| Format: | Fireside Chat |
| Date: | Wednesday, April 15th |
| Time: | 1:00 – 2:00 pm ET |
| Location: | Virtual |
| Webcast: | Register Here |
2026 Bloom Burton & Co. Healthcare Investor Conference, April 21-22, 2026
| Format: | Corporate Presentation and 1x1 Investor Meetings |
| Presentation Date: | Wednesday, April 22nd |
| Time: | 11:00 – 11:30 am ET |
| Location: | Toronto, Ontario |
| Webcast: | Register Here |
A live webcast and archived replay of the presentations will be available on the investors section of www.nervgen.com.
About NervGen Pharma
NervGen Pharma Corp. (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
Contacts
Huitt Tracey, Investors
htracey@nervgen.com
604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310
Cautionary Note Regarding Forward Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company's potentially best-in-class candidate, NVG-291; the potential broad therapeutic applications of NVG-291; NVG-291 as potentially the first approved pharmacologic treatment for chronic tetraplegia; and the creation of neuroreparative therapeutics to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company's actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's most recently filed Annual Information Form, which is available under the Company’s profile on SEDAR+ at www.sedarplus.ca (which are also incorporated in the recently filed form 40-F available on the website of the U.S. Securities and Exchange Commission (the “SEC") at www.sec.gov), including the management’s discussion & analysis for the year-ended December 31, 2025. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
